Drug-Pricing Report Blames U.S. Market-Based Economy
By Mari Serebrov
Monday, July 25, 2011
A policy climate change brought on by deficit talks and health care reform could make the U.S. market-based approach to drug pricing an endangered species.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.